# Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

> **NCT02490787** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 24 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** Concizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02490787
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-10
- **Primary completion:** 2016-10-14
- **Final completion:** 2016-10-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02490787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02490787, "Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02490787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*